AUTOZYME™ ACL Screen: A new addition to AUTOZYME™ ACL family…

ELY, Cambridgeshire, October, 2005 - Cambridge Life Sciences Ltd. is delighted to announce the launch of AUTOZYME™ ACL Screen.

Cambridge Life Sciences’ AUTOZYME™ ACL range is one of the most consistent anti-cardiolipin antibodies assays on the market, it is envied for it’s batch to batch and within batch consistency.The new AUTOZYME™ ACL Screen will be no exception.

Our Research and Development team have developed a non-selective ACL screen assay that contains all three antibody types – IgG, IgM and IgA. This makes AUTOZYME™ ACL Screen ideal as a first test for all new patients.

“Our argument for developing the AUTOZYME™ ACL Screen is that if you are going to screen surely you should cover all of the antibody types”; said Keith Rawson, Technical Director at Cambridge Life Sciences.

Reliability & Sensitivity:
In a blind study, we challenged AUTOZYME™ ACL Screen by asking it to correctly identify a whole host of NEQAS samples. This is the closest that we can come to mimicking life in a busy laboratory.The results were astonishing: 100% accuracy. The data is entirely transparent and we are happy to provide you with the findings as proof that AUTOZYME™ ACL Screen does not misclassify samples.If that was not enough, the AUTOZYME™ ACL Screen was also trialled in real laboratory conditions using both manual and automated sampling techniques. In both cases, the precision was reported as very good.

But, if you would like to put the AUTOZYME™ ACL Screen to the test in your laboratory; contact us directly. Our confidence in AUTOZYME™ ACL Screen is such that we challenge anyone to better it in terms of consistency and costs.

Cost reduction and Time Saving:
By moving from a testing regimen, which involves characterisation of each patient sample, to one where every sample is screened and then only the positives are characterised; there are considerable savings to be made, both in terms of kits costs and also technician time.

In many laboratories, the number of positive samples can be as low as 20 out of 100 tested, by switching to a screening regimen these laboratories could save 60% of their current costs.
AUTOZYME™ ACL Screen measures all three immunoglobulin sub classes in one well. The assay has a precision profile, which allows for the patient samples to be run as singles – in fact we recommend this in our protocol.

The AUTOZYME™ product range is manufactured by Cambridge Life Sciences in Ely, there are no distributor margins to pay which allows us to be very competitive in our pricing.If you would like to find out how much we could save you contact us on one of the customer support numbers and we will discuss the options.

About Cambridge Life Sciences Ltd.:
Cambridge Life Sciences Ltd. is a leading manufacturer and supplier of diagnostics primarily for autoimmune diseases and the clinical chemistry market, designed to meet the needs of today’s healthcare industry. Cambridge Life Sciences technology and services also includes collaborative research, research and development of biosensor technology and a Reference Laboratory that offers access to new, non-routine and infrequently run tests.